DASH SK, CHANDY MJAbstract--Alzheimers disease is the most common cause of dementia. The increasing prevalence of the disease presents a challenge to the treating neurologist. Presently the drugs used for Alzheimers disease produce only symptomatic improvement. Currently various therapeutic strategies are under development for the treatment and prevention of Alzheimers disease, like ? secretase inhibitors, immunotherapy with anti A? antibodies,A? immunization, metal protein attenuation compounds, and peroxysomal proliferators activated receptors ? agonist,NSAIDS. Alzheimers disease has a marked inflammatory component. It is proposed that anti inflammatory therapies may be of value in Alzheimers disease. PPARS are members of nuclear hormone receptor super families that are activated by lipids in regulating inflammatory responses. PPAR? has been investigated in animal model for its role due to its anti inflammatory action in various C.N.S. diseases, having an inflammatory component. PPAR ? agonists have been demonstrated to suppress amyloid ? mediated activation of microglia in vitro and to prevent cortical and hippocampal neuronal death. Various studies have shown that PPAR ? agonists may be of value in treatment of Alzheimers disease in animal models. The details of PPAR? agonists as a therapeutic target for the treatment of Alzheimers disease will be discussed.

Username
Password